Comparative study of Cefpodoxime

and to study the market potential for

’s product portfolio.

Started by Ranbir Singh and Gurbax

Singh 1937

Incorporated in

1961 and went public in 1973

June 2008, with Daiichi Sankyo

Ranbaxy & Daiichi Sankyo combined rank top 20 global pharmaceutical companies.

In public

Merger

Position

No. 1 Indian Pharma Company Global consolidated sales –US $ 1519 Mn (2009)

International 77%

Domestic 23%

Ginseng

Ofloxacin

Valacyclovir

Ciprofloxacin

Diclofenac

Amoxycillin

Cefpodoxime

Atorvastatin

Cephalexin

Ceftriaxone

Isotretinoin

Rantidine

Imipenem

Co-amoxyclav

Loratadine

Ketorolac

Simvastatin

(Cefpodoxime proxetil) is an orally administered, extended spectrum, semi-syntheticantibiotic of the cephalosporin class.

Microbiology:

Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime.

FOR PRODUCT PORTFOLIO ◦ CEPODEM-XP (Cefpodoxime + Clavulanic Acid)

◦ CEROXIM (Cefuroxime)

◦ CEROXIM-XP (Cefuroxime + Clavulanic Acid)

◦ RACIPER (Esomeprazole)

◦ RICONIA (Multivitamin)

◦ ALTRAFLAM (Aceclofenac)

◦ SYNASMA (Doxofylline)

◦ & GEMBAX (Gemifloxacin)

To know the market share of the

Ranbaxy’s Products in Ranbaxy

(Pharma) Section.

To know about the current products that

are giving a tough competition to

Ranbaxy.

To know about the new competitors that

have entered into the market and are

trying to capture some of it’s share.

1

2

3

Type of Research: Exploratory research

Sample unit: Retailer

Sample extent: South Delhi

Sampling technique: Convenient sampling

Sample size: 100 Retailers

Data collection methods:

Primary methods: (a)Face to face interactions (b) Questionnaire

Secondary methods: Company manuals ,Journals ,Magazines & Internet

Analysis technique

Microsoft Excel has been used for the statistical analysis.

Limitations:

Sometime respondents refuse to cooperate and it may possible that they give biased and dishonest answers.

SALE OF CEPODEM STRIP/WEEK

0

10

20

30

40

50

60

70

80

90

CEPODEM CEPODEM-XP CEROXIM CEROXIM-XP RACIPER RICONIA ALTRAFLAM-P SYNASMA GEMBAX

Ranbaxy Product sales/week

OVERALL AIIMS MALVIYA NAGAR CHITTARANJAN PARK

JANGPURA---BHOGAL NEW FRIENDS COLONY JAMIA NAGAR(OKHLA) OKHLA (FORTIS HOSPITAL)

Cost factor

Advertisement in medical journals.

More profit and replacement schemes to the chemists

Availability of products

Frequent Doctors Visit.